The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The InterVitaminK Trial - Effects of Vitamin K Supplementation on Cardiovascular, Metabolic, and Bone Health (InterVitaminK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05259046
Recruitment Status : Recruiting
First Posted : February 28, 2022
Last Update Posted : April 14, 2023
Sponsor:
Information provided by (Responsible Party):
Allan Linneberg, Bispebjerg Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to examine the effect of menaquinone-7 (MK-7) supplementation on cardiovascular, metabolic, and bone health.

Condition or disease Intervention/treatment Phase
Coronary Artery Calcification Arterial Stiffness Dietary Supplement: Menaquinone-7 (MK-7) tablet (333 µg) Dietary Supplement: Placebo tablet Not Applicable

Detailed Description:

Background: Research suggest that vitamin K may have protective effects against non-communicable and age-related diseases as diverse as cardiovascular disease (CVD), osteoporosis, and type 2 diabetes (T2D). However, there is a need for larger studies investigating the potential health effects of vitamin K in the general population.

Objective: The objective of the InterVitaminK trial is to investigate the effects of vitamin K (menaquinone-7, MK-7) supplementation on cardiovascular, metabolic, and bone health.

Hypothesis: The primary hypothesis is that vitamin K supplementation will reduce the progression of coronary artery calcification (CAC) with 15% compared with placebo.

Methods: The InterVitaminK trial is a double-blinded, placebo-controlled, randomized intervention trial. The trial will be conducted in Denmark at the Center for Clinical Research and Prevention and the CT scans will be performed at Rigshospitalet, Denmark. Participants from the Inter99 cohort with detectable CAC (Agatson score >=10) are eligible for the trial. Participants will be randomized 1:1 to receive one daily tablet with MK-7 or placebo for a period of 3 years. Randomization is done in blocks of 6 using computer generated random numbers. Participants are invited for a health examination at baseline and after 1, 2, and 3 years intervention. CT scans are performed at baseline and at 3-year follow-up.

Outcomes: The primary study outcome is progression of CAC from baseline to 3-year follow-up, assessed by Cardiac CT scans. Secondary outcomes are bone mineral density, pulmonary function, and biomarkers of insulin resistance.

Power: Power calculation and sample size considerations are based on the primary endpoint (three-year progression in CAC). A total of 450 participants will be enrolled in the trial. Based on a previous vitamin K trial and data from the Danish cohort study DANCAVAS, it is assumed that the geometric mean three-year progression in CAC in the control group participants is 3.0 with an SD of 1.3. The hypothesis is that vitamin K supplementation can reduce the three-year progression in CAC by 15%. With an estimated dropout-rate of 25% during the study period, a total of 450 participants (225 participants in each group) enrolled at baseline, will provide 89% power to demonstrate an effect of at least 15% (alpha 0.05).

Statistical analyses: The effect of vitamin K supplementation on the primary outcome (CAC) will be analyzed using mixed effects linear regression. The mixed effects linear regression will include a fixed effect for group allocation (intervention/control), a fixed effect for time point (baseline and 3-year follow-up), fixed effect for baseline CAC score and an interaction between group allocation and time point. As baseline measurements are conducted prior to enrolment, treatment at baseline will be modelled as a common treatment category, constraining baseline measurements to no systematic treatment effect between the two arms. The mixed effects model will include a random intercept for each enrolled participant and a first order autoregressive correlation structure allowing correction of measurement for the same participant with higher correlation for measurements closer in time.

Likewise, secondary outcomes and supportive outcomes will be analyzed using mixed effects linear regression. Analysis and presentation of data will be in accordance with the CONSORT guidelines. For details, see the statistical analysis plan uploaded at clinicaltrials.gov (NCT05259046).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized in a double-blinded manner 1:1 to MK-7 tablets or placebo tablets. Randomisation is conducted in blocks of 6 using computer generated random numbers. A total of 450 participants will be enrolled (225 in each group).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Participants, data collectors, and investigators are blinded of the allocation throughout the study period. The randomization list is generated and kept by a statistician employed at the Center for Clinical Research and Prevention, but not involved in the trial. Kappa Bioscience AS, Oslo, Norway, keeps the randomization list for labelling of investigational products. The randomization list will be made available to one DSMB member if safety concerns arise during the study period.
Primary Purpose: Prevention
Official Title: Novel Health Effects of Vitamin K: a Placebo-controlled Randomized Trial in the General Population (InterVitaminK)
Actual Study Start Date : June 21, 2022
Estimated Primary Completion Date : October 1, 2026
Estimated Study Completion Date : December 1, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin K
Drug Information available for: Menadione

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention
Intervention treatment . Dietary supplementation with Menaquinone-7 (MK-7) tablet (333 µg/day). MK-7 (K2VITAL®DELTA) tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
 Dietary Supplement: Menaquinone-7 (MK-7) tablet (333 µg)
One MK-7 tablet containing 333 µg MK-7 per day
Placebo Comparator: Placebo
Placebo tablet (no active treatment). The placebo tablets will match the intervention treatment in both taste and appearance. Placebo tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
 Dietary Supplement: Placebo tablet
One placebo tablet per day


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Total coronary artery calcification [ Time Frame: Baseline to three years of follow-up ]
    Total coronary artery calcification score (unit: Agatston score) in the coronary arteries, assessed by non-contrast Cardiac CT scans. A high score reflects higher degree of calcification in the coronary arteries and increased risk of coronary artery disease. The outcome will be evaluated by randomization group (active versus placebo).


Secondary Outcome Measures :
  1. Coronary plaque composition [ Time Frame: Baseline to three years of follow-up ]
    Total coronary plaque composition (calcified, non-calcified subcomponents) assessed by contrast Cardiac CT scans (unit: cubic millimeters)

  2. Arterial stiffness [ Time Frame: Baseline to three years of follow-up ]
    Arterial stiffness assessed by carotid-femoral pulse wave velocity examination (unit: meters/second)

  3. Blood pressure [ Time Frame: Baseline to three years of follow-up ]
    Blood pressure (unit: millimeter of mercury) assessed by a digital blood pressure device. Both systolic and diastolic blood pressure will be evaluated.

  4. Aortic valve calcifications [ Time Frame: Baseline to three years of follow-up ]
    Aortic valve calcifications assessed by non-contrast Cardiac CT scans (unit: Agatston score). A high score reflects higher degree of calcification

  5. Bone mineral density [ Time Frame: Baseline to three years of follow-up ]
    Bone mineral density assessed by quantitative CT scan of the columna thoracalis (unit: milligrams/cubic centimeter)

  6. Pulmonary function [ Time Frame: Baseline to three years of follow-up ]
    Pulmonary function reflected by forced expiratory volume in one second (FEV1) (unit: Volume in Liter)

  7. Insulin resistance [ Time Frame: Baseline to three years of follow-up ]
    Insulin resistance assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (unit: millimoles/liter * picomoles/liter)


Other Outcome Measures:
  1. Biomarkers of bone resorption [ Time Frame: Baseline to three years of follow-up ]
    Bone metabolism reflected by biomarkers of bone resorption including C-terminal telopeptide of type I collagen (CTX) (unit: picograms/milliliter)

  2. Biomarkers of bone formation [ Time Frame: Baseline to three years of follow-up ]
    Bone metabolism reflected by biomarkers of bone formation including osteocalcin (with different phosphorylation and carboxylation forms) (unit: nanograms/milliliter), Fibroblast growth factor 23 (FGF23) (unit: nanograms/milliliter), osteoprotegerin (unit: Picomoles/liter), and Procollagen 1 Intact N-Terminal Propeptide (P1NP) (unit: milligram/liter)

  3. Lung function [ Time Frame: Baseline to three years of follow-up ]
    Lung function reflected by expiratory forced vital capacity (FVC) and FEV1/FVC-ratio

  4. Lung tissue density [ Time Frame: Baseline to three years of follow-up ]
    Lung tissue density as a measure of lung fibrosis assessed by CT scan

  5. Respiratory infections [ Time Frame: Baseline to three years of follow-up ]
    Annual number of respiratory infectious disease episodes, both upper and lower respiratory infections including COVID-19 (registered through telephone interviews)

  6. Glucose control [ Time Frame: Baseline to three years of follow-up ]
    Glucose metabolism reflected by Glycated hemoglobin A1c (HbA1c) (unit: millimole/mol)

  7. Lipid metabolism [ Time Frame: Baseline to three years of follow-up ]
    Lipid metabolism biomarkers (including total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein) (unit: milligrams/deciliter)

  8. Inflammation [ Time Frame: Baseline to three years of follow-up ]
    Inflammatory biomarkers including interleukin-6 (IL-6) (unit: picograms/milliliter) and Tumor necrosis factor α (TNF-α) (unit: picograms/milliliter).

  9. Body composition [ Time Frame: Baseline to three years of follow-up ]
    Anthropometry reflected by body fat percentage (%) assessed by bioimpedance (unit is estimated per cent fat mass).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Detectable CAC (Agatson score >=10) assessed by Cardiac Computed Tomography (CT) scan in the Inter99 20-year follow-up study

Exclusion Criteria:

  • Manifest CVD (prior cerebral infarct, prior myocardial infarct, prior percutaneous coronary intervention or prior coronary artery bypass surgery)
  • Noise on the CT scan, which complicates an accurate assessment of CAC and interpretation of the CT scan. An example is a pacemaker
  • Current treatment with Vitamin K antagonist (VKA).
  • History of coagulation disorders (hemophilia, von Willebrand disease, sickle cell anemia)
  • Active malignant disease (ongoing treatment)
  • Previous surgical removal of the thyroid gland, or one or more of the parathyroid glands
  • Regular use of vitamin K supplements other than trial tablets
  • Pregnancy or breastfeeding
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05259046


Contacts
Layout table for location contacts
Contact: Allan Linneberg, MD +45 38163118 allan.linneberg@regionh.dk
Contact: Freja B Kampmann, MSc +45 22420122 freja.bach.kampmann.02@regionh.dk

Locations
Layout table for location information
Denmark
Center for Clinical Research and Prevention Recruiting
Copenhagen, Glostrup, Denmark, DK-2600
Contact: Freja B Kampmann, MSc         
Sponsors and Collaborators
Bispebjerg Hospital
  Study Documents (Full-Text)

Documents provided by Allan Linneberg, Bispebjerg Hospital:
Statistical Analysis Plan  [PDF] January 10, 2023

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Allan Linneberg, Director, Professor, MD, PhD, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT05259046    
Other Study ID Numbers: InterVitaminK
First Posted: February 28, 2022    Key Record Dates
Last Update Posted: April 14, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: After the publication of the main results upon completion of the trial, data will be available on a collaborative basis following approval from the InterVitaminK Trial Steering Committee and the regional data protection authority.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcinosis
Calcium Metabolism Disorders
Metabolic Diseases
Vitamin K 2
Vitamin K
Menaquinone 7
Antifibrinolytic Agents
 Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants
Vitamins
Micronutrients
Physiological Effects of Drugs